| |
Dementia cases
|
Time to incidence for dementia cases (months)
|
Time to end of study for non-dementia cases (months)
| |
---|
Drug
|
Sample size (n)
|
n
|
%
|
Mean
|
SD
|
Mean
|
SD
|
Model 3: HR for incidence of dementia vs CV (95% CI)
|
---|
CV
|
394 739
|
3359
|
0.85
|
19.8
|
8.0
|
30.3
|
8.6
| |
Atorvastatin
|
53 869
|
275
|
0.51
|
19.5
|
7.7
|
23.9
|
11.6
|
0.91 (0.80–1.02)
|
Lovastatin
|
54 052
|
439
|
0.81
|
19.1
|
7.9
|
29.7
|
8.1
|
0.95 (0.86–1.05)
|
Simvastatin
|
727 128
|
2647
|
0.36
|
19.3
|
7.8
|
29.1
|
8.0
|
0.46 (0.44–0.48)
|
- CV, cardiovacular.
- Column 1, medication group; column 2, sample size; column 3, number of dementia cases recorded during the course of the analytic period; column 4, percentage of dementia cases (calculated by dividing the value in column 3 by that in column 2); columns 5 and 6, number of months between start of the analytic period and incidence of dementia, and standard deviation (SD); columns 7 and 8, number of months between start of the analytic period and point at which subjects not receiving a diagnosis of dementia were censored due to the end of the analytic period, and SD.
- Hazard ratio for incidence of dementia based on the results from model 3 (Table 2).